Gene Loss In Tadpoles Triggers Seizures And Brain Leaks

What was studied

Researchers studied what happens when the AP3B2 gene stops working in a frog tadpole model. AP3B2 loss-of-function variants are known to cause DEE48, a severe early-onset neurodevelopmental epilepsy in people. To model this, the team used CRISPR to disrupt the matching gene, ap3b2, in Xenopus laevis tadpoles.

They then looked at behavior, brain activity, gene activity across the whole brain, and blood-brain barrier integrity. They also tested whether losartan, a drug that blocks angiotensin receptors, could improve some of the abnormal findings.

What they found

Compared with sibling control tadpoles, the ap3b2 CRISPR tadpoles were more active and had frequent seizure-like episodes. Brain imaging showed spontaneous neural activity that was larger, longer, more widespread, and more synchronized between the two sides of the brain.

Whole-brain gene testing found mainly reduced expression of brain-expressed genes, with over-representation of pathways linked to ion transport, axon formation and guidance, inhibitory (GABA) neurotransmission, and transport across the blood-brain barrier. In a barrier test, the CRISPR tadpoles showed faster leakage of sodium fluorescein, consistent with reduced blood-brain barrier integrity. Losartan significantly reduced hyperactive movement and tended to lower abnormal brain activity, but the improvement was incomplete.

Limits of the evidence

This was an animal study in CRISPR-edited frog tadpoles, not a study in children or adults with DEE48. The model was described as mosaic F0, which means not every cell necessarily had the same gene change, so it may not fully match the human condition.

The study links AP3B2 loss with seizures, gene-expression changes, and altered blood-brain barrier integrity, but it cannot fully establish how each change contributes to seizures. The losartan results were acute and incomplete in this model, so the study does not show that losartan or similar drugs are effective treatments for people with DEE48.

For families and caregivers

This study gives early clues about why AP3B2-related epilepsy may happen. It suggests that AP3B2 loss may affect nerve signaling, brain development, and blood-brain barrier integrity.

For families, this may matter because it points researchers toward more than one possible treatment pathway. Standard seizure medicines that affect ion transport or GABA may still be important, and future research may also explore treatments aimed at neuroinflammation or blood-brain barrier-related changes. But these ideas are still experimental and not proven for patients from this study alone.

What to watch next

Useful next steps would include studies in human cells or patients, and further testing of whether treatments targeting neuroinflammation or blood-brain barrier-related changes can safely reduce seizures in models that more closely match DEE48.

Terms in this summary

loss-of-function variant

A gene change that makes a protein work poorly or not work at all.

DEE48

A developmental and epileptic encephalopathy linked to AP3B2 gene changes.

CRISPR

A lab tool used to change or disrupt genes.

transcriptome

A readout of which genes are turned on or off in cells or tissue.

GABA

A major brain chemical that usually helps calm nerve activity.

blood-brain barrier

A protective lining of blood vessels that helps control what enters the brain.

interhemispheric synchrony

Brain activity on the left and right sides happening more closely together in time.

losartan

A medicine usually used for blood pressure that blocks angiotensin receptors.